BRAF-Directed Therapy in Metastatic Colorectal Cancer
Authors:
- 1 May 2016
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 22 (3) , 175-178
Abstract
Activating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limited efficacy, in contrast to metastatic melanoma. Combination strategies that block not only BRAF mutated kinase but other alternative pathways are ongoing and have demonstrated improved activity. This review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.Keywords
This publication has 33 references indexed in Scilit:
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerJournal of Clinical Oncology, 2015
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015
- Elucidating the prognostic significance ofKRAS,NRAS,BRAFandPIK3CAmutations in Chinese patients with metastatic colorectal cancerAsia-Pacific Journal of Clinical Oncology, 2015
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancerBMC Cancer, 2015
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer PrognosticationJNCI: Journal of the National Cancer Institute, 2013
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid CarcinomasCancer Discovery, 2013
- A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the ExtremityAnnals of Surgical Oncology, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- Mutations of the BRAF gene in human cancerNature, 2002